Lazard Capital, same company handling Enzon sale, is recommending Nector as a BUY today.
Nector is the sister company to Enzon. Yet Nector has hasn't the book value ,or the cash that Enzon
has ,and yet trading near $9 a share with twice the number of shares outstanding. What does this tell
Actually has close to three times the number of shares outstanding and a book value of 1/4 of Enzon's with less total net capital in cash.
It tells me some biotech will be getting a great deal acquiring ENZN. I'm now thinking we get $10+ for this cash cow.
Sentiment: Strong Buy